Group 1 - South Africa is experiencing the most severe foot-and-mouth disease outbreak in its history, with rapid virus transmission and strong infectivity, posing an unprecedented disaster for the livestock industry [1] - The outbreak began in April 2025 in KwaZulu-Natal province and has spread to other key agricultural areas, prompting the South African Department of Agriculture to procure vaccines for emergency vaccination of 930,000 animals [1] - The outbreak highlights the importance of global animal disease prevention and presents overseas market expansion opportunities for domestic animal health companies with technological advantages [1] Group 2 - The animal health industry has a tightly linked upstream and downstream, with upstream raw material drug companies providing essential support for vaccine production, while downstream demand from farming recovery and overseas epidemic prevention needs drive industry growth [2] - Companies like Reap Bio focus on veterinary biological products, including foot-and-mouth disease vaccines, covering multiple sectors such as pigs, poultry, and pets [3] - Bio Company is a leading domestic animal health enterprise with designated production qualifications for strong immunity foot-and-mouth disease vaccines, consistently ranking first in the industry for vaccine batch approvals [4]

从资金流向上来看，当日动物保健板块主力资金净流入1429.81万元，游资资金净流出3379.23万元，散户 资金净流入1949.42万元。动物保健板块个股资金流向见下表： 证券之星消息，1月6日动物保健板块较上一交易日上涨0.83%，*ST绿康领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 37.17 | 5.00% | 7510.0 | 2772.39万 | | 300871 | 回盛生物 | 21.92 | 3.15% | 9.40万 | 2.03亿 | | 920970 | 大禹生物 | 7.95 | 2.71% | 1.84万 | 1449.96万 | | 920729 | 永顺生物 | 8.90 | 2.06% | 1.12万 | 992.55万 | | 920275 | 驱动力 | 9.05 | 1.57% | 1.01 ...

Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

Investment Rating - The industry investment rating is "Positive" and is maintained [5] Core Viewpoints - The pig farming sector is expected to benefit from recent policies and market dynamics that promote capacity reduction, leading to a potential price turning point in Q2 2026, with long-term performance improvements anticipated for related stocks [3][43] - The structural growth trend in the post-cycle sector continues, with profits likely to gradually transmit downstream if the current round of pig capacity reduction proceeds smoothly, benefiting the animal health sector [3] - The planting chain shows a confirmed upward trend in grain prices, indicating favorable fundamentals for planting and seed industries, highlighting significant investment opportunities [3] - The pet food sector is experiencing growth and price increase logic, with continuous recognition of domestic brands and sustained growth of leading companies [3] Summary by Sections Pig Farming - The average price of live pigs as of December 31 was 12.76 yuan/kg, a week-on-week increase of 10.38%, while the average price of 15 kg piglets was 19.44 yuan/kg, up 2.21% week-on-week [12][51] - The supply side shows a widening price gap for fattened pigs, supporting price increases, while demand is boosted by consumption expectations during the New Year holiday [12][17] Poultry - The price of white feather broilers increased to 7.82 yuan/kg, up 6.39% week-on-week, and chick prices rose to 3.59 yuan/chick, up 1.7% week-on-week [17][51] - The supply of meat chickens has increased, leading to a more relaxed market supply, while demand has weakened due to some slaughterhouses reducing operations [17] Feed Sector - The prices of corn, wheat, and soybean meal have risen, with corn averaging 2351.57 yuan/ton, up 0.57% week-on-week, and soybean meal at 3172.29 yuan/ton, up 0.96% week-on-week [27][51] - Increased selling enthusiasm among farmers is noted, although the pace of supply remains slow [27] Major Agricultural Products - The domestic natural rubber futures price was 15605 yuan/ton as of December 31, down 0.29% week-on-week, with inventory levels increasing [38][51] - The current down cycle for sugar prices continues, with no significant recovery expected [39]

截至2025年12月31日收盘，回盛生物（300871）报收于20.73元，较上周的20.61元上涨0.58%。本周， 回盛生物12月31日盘中最高价报21.01元。12月29日盘中最低价报20.43元。回盛生物当前最新总市值 41.94亿元，在动物保健板块市值排名8/11，在两市A股市值排名3819/5181。 武汉回盛生物科技股份有限公司于2025年12月26日收到首期政府补助资金225.00万元，项目补助总金额 为1,000.00万元，分阶段拨付。本次补助为与收益相关的政府补助，与日常经营活动相关，已实际到 账，占公司最近一期经审计净利润绝对值的11.16%。该笔补助不会对公司2025年度利润产生影响，未 来将根据项目进展对公司产生积极影响。具体会计处理以年度审计结果为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 本周关注点 公司公告汇总：回盛生物收到首期政府补助资金225.00万元，占最近一期经审计净利润绝对值的 11.16%。 公司公告汇总 ...

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

Group 1 - The core view of the report emphasizes a structural transformation in the capital market, focusing on rebuilding confidence and addressing external demand pessimism [3][4] - The investment logic suggests a shift from cyclical growth to cyclical value, with a resilient cycle expected in 2026, highlighting the value attributes of leading companies [9] - Key assumptions include a gradual decrease in the breeding sow inventory and proactive capacity control by pig companies, which may lead to reduced supply pressure and potential price recovery for pigs in 2026 [8] Group 2 - The report identifies specific companies to focus on, such as leading low-cost and high-certainty firms like Muyuan Foods and Wens Foodstuffs, as well as high-growth smaller pig companies [7] - The report outlines potential risks, including the possibility of breeding sow inventory not decreasing as expected, which could lead to an oversupply of pigs and downward pressure on prices [8] - The report also discusses the beef market, indicating that if the import impact continues, it could lead to downward pressure on beef prices, affecting the profitability of beef companies [16][24] Group 3 - In the poultry sector, the report highlights that the yellow chicken market may see price increases if breeding stocks continue to decline, while the white chicken market is expected to recover as macroeconomic activities improve [25][26] - The report emphasizes the importance of consumer demand in the poultry market, noting that weak demand could lead to price declines and pressure on company performance [27][32] - The report suggests that the animal health sector will benefit from the recovery of livestock profitability, with a focus on companies that have strong R&D capabilities and product pipelines [33][36] Group 4 - The grain sector is expected to see upward price trends due to adverse weather conditions affecting crop yields, with a focus on companies involved in seed production and transgenic varieties [40][41] - The report warns of potential risks in the seed industry, including weak demand for new varieties, which could lead to price declines and increased pressure on seed companies [44][45] - The report highlights the importance of monitoring government policies regarding the commercialization of new seed varieties, as delays could impact market expectations [46][48] Group 5 - The report provides a risk assessment for recommended stocks, such as Muyuan Foods and Wens Foodstuffs, indicating potential risks related to pig output and price declines [50][56] - The report emphasizes the need for continuous monitoring of key indicators, such as breeding sow inventory and market prices, to assess the performance of the companies in the livestock sector [56]

南财智讯12月30日电，金河生物公告，公司于2025年12月30日召开第六届董事会第三十五次会议，审议 通过了《关于回购注销部分限制性股票的议案》。鉴于公司2023年限制性股票激励计划首次授予的1名 激励对象因其他原因身故，不再具备激励对象资格，公司拟回购注销其已获授但尚未解除限售的限制性 股票合计30,000股，占回购注销前公司总股本的0.0039%。本次回购价格为2.29元/股加上中国人民银行 同期存款利息之和，回购总金额为6.87万元及相应利息，资金来源为公司自有资金。该事项尚需提交公 司2026年第一次临时股东会审议。 ...

健康元公告，2025年12月30日，公司召开董事会，审议通过了《关于出售资产暨关联交易的议案》。公 司拟将持有的毛孩子动物保健（广东）有限公司49%股权转让给关联方深圳市心有毛孩投资合伙企业 （有限合伙），交易价格为5145万元。同时，心有毛孩拟认购毛孩子1500万元新增注册资本，增资价款 为1500万元。交易完成后，心有毛孩将持有毛孩子52.56%的股权，公司控股子公司丽珠集团将持有毛 孩子47.44%的股权，公司将不再直接持有毛孩子股权，毛孩子不再纳入公司合并报表范围内。 ...

截至2025年12月29日收盘，回盛生物(300871)报收于20.7元，上涨0.44%，换手率2.48%，成交量5.01万 手，成交额1.03亿元。 当日关注点 武汉回盛生物科技股份有限公司于2025年12月26日收到首期政府补助资金225.00万元，项目补助总金额 为1,000.00万元，分阶段拨付。本次补助为与收益相关的政府补助，与日常经营活动相关，已实际到 账，占公司最近一期经审计净利润绝对值的11.16%。该笔补助不会对公司2025年度利润产生影响，未 来将根据项目进展对公司产生积极影响。具体会计处理以年度审计结果为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：12月29日主力资金净流入608.96万元，散户资金呈净流出态势。 来自公司公告汇总：回盛生物于12月26日收到首期政府补助225.00万元，占公司最近一期经审计 净利润绝对值的11.16%。 交易信息汇总资金流向 12月29日主力资金净流入608.96万元；游资资金净流入428.5万元；散户资金净流出1037.46万元。 公司公告汇总关于 ...